The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats

Mitsuko Takenaga, Yuki Ohta, Yukie Tokura, Akemi Hamaguchi, Koichi Shudo, Hideyuki Okano, Rie Igarashi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume32
Issue number2
DOIs
Publication statusPublished - 2009 Feb

Fingerprint

Retinoids
Spinal Cord Injuries
Protein-Tyrosine Kinases
Brain-Derived Neurotrophic Factor
Cell Survival
Nerve Growth Factor Receptors
Benzoic Acid
Myelin Basic Protein
Neural Stem Cells
Glial Fibrillary Acidic Protein
Myelin Sheath
Tretinoin
Astrocytes
Neurodegenerative Diseases
Thymidine
Cell Differentiation
tamibarotene
Gene Expression
Neurons
Wounds and Injuries

Keywords

  • Am-80
  • Neurotrophic factor
  • Retinoid
  • Spinal cord injury

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats. / Takenaga, Mitsuko; Ohta, Yuki; Tokura, Yukie; Hamaguchi, Akemi; Shudo, Koichi; Okano, Hideyuki; Igarashi, Rie.

In: Biological and Pharmaceutical Bulletin, Vol. 32, No. 2, 02.2009, p. 225-231.

Research output: Contribution to journalArticle

Takenaga, Mitsuko ; Ohta, Yuki ; Tokura, Yukie ; Hamaguchi, Akemi ; Shudo, Koichi ; Okano, Hideyuki ; Igarashi, Rie. / The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats. In: Biological and Pharmaceutical Bulletin. 2009 ; Vol. 32, No. 2. pp. 225-231.
@article{3ca5e36ef26c4124af594aa47d75c807,
title = "The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats",
abstract = "The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.",
keywords = "Am-80, Neurotrophic factor, Retinoid, Spinal cord injury",
author = "Mitsuko Takenaga and Yuki Ohta and Yukie Tokura and Akemi Hamaguchi and Koichi Shudo and Hideyuki Okano and Rie Igarashi",
year = "2009",
month = "2",
doi = "10.1248/bpb.32.225",
language = "English",
volume = "32",
pages = "225--231",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "2",

}

TY - JOUR

T1 - The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats

AU - Takenaga, Mitsuko

AU - Ohta, Yuki

AU - Tokura, Yukie

AU - Hamaguchi, Akemi

AU - Shudo, Koichi

AU - Okano, Hideyuki

AU - Igarashi, Rie

PY - 2009/2

Y1 - 2009/2

N2 - The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.

AB - The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.

KW - Am-80

KW - Neurotrophic factor

KW - Retinoid

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=60749113185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749113185&partnerID=8YFLogxK

U2 - 10.1248/bpb.32.225

DO - 10.1248/bpb.32.225

M3 - Article

VL - 32

SP - 225

EP - 231

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 2

ER -